Patents by Inventor Mariano Barbacid

Mariano Barbacid has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6271242
    Abstract: A novel method for preventing, stabilizing or causing regression of cancer is disclosed. The method comprises administering to a patient in need thereof a tyrosine protein kinase inhibitor.
    Type: Grant
    Filed: February 10, 1992
    Date of Patent: August 7, 2001
    Assignee: Bristol-Myers Squibb Co.
    Inventor: Mariano Barbacid
  • Patent number: 6087349
    Abstract: A method is provided by blocking or preventing the prenylation of CAAX box containing proteins including ras oncogene products thereby preventing and/or treating ras-related tumors which includes the step of administering a therapeutically effective amount of a protein-prenyl transferase inhibitor.
    Type: Grant
    Filed: May 6, 1998
    Date of Patent: July 11, 2000
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Scott A. Biller, Mariano Barbacid, Eric M. Gordon, David R. Magnin, Chester A. Meyers, Veeraswamy Manne
  • Patent number: 5919650
    Abstract: Method for inactivating the function produced by a protein using an intracellularly expressed antibody or fragment thereof.
    Type: Grant
    Filed: April 22, 1990
    Date of Patent: July 6, 1999
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Mariano Barbacid, Ximena Montano
  • Patent number: 5625121
    Abstract: The present invention provides mice and mouse cell lines having a homozygous or heterozygous deficiency in a gene encoding a neurotrophin receptor. In a preferred embodiment of this invention, mice and cell lines carry a trkB locus specifically targeted within its tyrosine protein kinase sequences. Mice homozygous for this mutation express gp95.sup.trkB receptor of unknown function but not the high affinity functional gp145.sup.trkB tyrosine protein kinase receptors. This mutation results in multiple CNS and PNS neuronal deficiencies and in a postembryonic lethal phenotype. Such genetically modified mice are useful in model systems for studying human diseases involving neuronal degeneration and neuronal cell loss, as well as in screening for genes, proteins, or other compounds that may prevent or impede neuronal cell death or stimulate neuronal regeneration.
    Type: Grant
    Filed: October 14, 1993
    Date of Patent: April 29, 1997
    Assignee: Bristol-Myers Squibb Company
    Inventors: Rudiger Klein, Alexandra Joyner, Mariano Barbacid
  • Patent number: 5348864
    Abstract: Nucleic acid sequences, particularly DNA sequences, coding for all or part of a vav mouse proto-oncogene protein or for a modified vav mouse proto-oncogene protein, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials. The invention also concerns polypeptide molecules comprising all or part of a vav mouse proto-oncogene protein or a modified vav mouse proto-oncogene protein, and methods for producing these polypeptide molecules.
    Type: Grant
    Filed: January 25, 1991
    Date of Patent: September 20, 1994
    Assignee: E. R. Squibb & Sons, Inc.
    Inventor: Mariano Barbacid
  • Patent number: 5348856
    Abstract: Nucleic acid sequences, particularly DNA sequences, coding for all or part of a trkC protein, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials. The invention also concerns polypeptide molecules comprising all or part of a trkC protein and methods for producing these polypeptide molecules.
    Type: Grant
    Filed: July 7, 1992
    Date of Patent: September 20, 1994
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Mariano Barbacid, Fabienne Lamballe
  • Patent number: 5185248
    Abstract: Assays for farnesyl-protein transferase (FT) which can be used to identify substances that block the farnesylation of ras oncogene products are described. Because farnesylation is required for ras oncogene activity, inhibitory compounds identified in the assays of the invention can block neoplastic transformation mediated by the ras oncogene. The assays of the invention are targeted for a step subsequent to the synthesis of farnesyl pyrophosphate (FPP), the donor of the farnesyl residue, and an intermediate in cholesterol synthesis and other important cellular pathways. Therefore, compounds which inhibit ras mediated transformation, yet do not cause major disruptions of important cell pathways that require FPP as an intermediate may be identified using the assays of the invention.
    Type: Grant
    Filed: May 8, 1990
    Date of Patent: February 9, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Mariano Barbacid, Veeraswamy Manne